Approaching healthcare innovation with ingenuity, passion and courage to create new solutions to difficult medical challenges. Guidelines: bit.ly/3CMYyZW
Joined June 2017
- Tweets 972
- Following 214
- Followers 64,053
- Likes 51
793 Photos and videos
Thank you to everyone who joined this year’s Clinical Trials at the Summit. Ocugen Chairman, CEO, and Co-Founder @drsmusunuri joined industry leaders for a panel discussion on IRDs and the importance of advancing innovative gene therapies. $OCGN #GeneTherapy #Biotech
16
80
2,212
Please join us in welcoming Mohamed Genead, MD, MSc as #Ocugen’s CMO.
With 20 years of experience in ophthalmology, gene therapy, and retinal disease development, Dr. Genead brings extensive leadership and expertise as we advance transformative therapies for patients.
12
96
4,540
What makes #OCU400 different?
OCU400 is designed to address multiple RP mutations through a potential one-time therapy.
Follow us for updates as we advance OCU400 toward a planned BLA submission this year.
#RetinitisPigmentosa #GeneTherapy $OCGN
32
121
5,270
Early #OCU410ST results show:
✓ 54% reduction in atrophic lesion growth
✓ 100% of treated eyes stabilized or improved
✓ 6 letter gain in visual acuity
Hear from an OCU410ST clinical trial participant: bit.ly/3Q9CBiI
$OCGN
40
143
5,509
What is #RetinitisPigmentosa (RP)?
RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN
39
105
2,852
Ocugen is excited to showcase our innovative modifier #genetherapy platform for inherited retinal and blindness diseases at three conferences this month. @IAmBiotech @NobleCapMkts $OCGN #InvestorRelations
🔗bit.ly/4o2nkwJ
Noble Capital replay: bit.ly/4vkPqpl
31
124
3,643
100,000 people with #Stargardtdisease have no FDA approved treatment. #OCU410ST aims to slow or stop disease progression, with early promising data.
Follow Ocugen and be part of something groundbreaking. #Biotech #Genetherapy $OCGN
36
144
6,050
Tune in on May 26, 2026, as Ocugen CEO @drsmusunuri participates in the Stifel 2026 Virtual Ophthalmology Forum. @Stifel #GeneTherapy #InvestorRelations $OCGN
Watch live: bit.ly/4wETPVB
Replay available for 30 days following the event: ir.ocugen.com
15
77
2,795
What is #Stargardtdisease?
A rare inherited retinal disease that can cause central vision loss, often beginning early in life. Ocugen’s investigational #genetherapy candidate, #OCU410ST, is designed to target disease pathways. #Biotech $OCGN
25
103
3,669
Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.
Learn more: bit.ly/4wrB1Jm
#GeneTherapy #Biotech #FinancialUpdate $OCGN
27
126
8,006
Impactful day in Ft. Lauderdale at #RetinaWorldCongress as CEO @drsmusunuri shared how Ocugen is advancing potentially one-time gene therapies for RP, Stargardt disease, and GA, while working toward three BLA filings by 2028.
@RWCRetina #GeneTherapy #Biotech $OCGN
20
88
4,006
During #ARVO2026, Ocugen shared a poster presentation on reducing variability in quantitative autofluorescence measurements through automation for #geographicatrophy & #Stargardtdisease. Proud to support innovation advancing research for blindness diseases. $OCGN #AMD @ARVOinfo
19
79
2,731
Today, CEO @drsmusunuri announced 1Q 2026 update:
• Cash runway into 2028
• Positive #OCU410 data
• Enrollment complete for #OCU400 & #OCU410ST
• Progress toward BLA filings
Read: bit.ly/4tS7XJv
#EarningsUpdate #Genetherapy $OCGN
26
123
7,263
What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual function. Share this with someone who should know more about EZ.
#EyeHealth #Biotech #Retina #Ophthalmology #AMD #StargardtDisease
18
82
4,298
Don’t miss it. Ocugen will host a live webcast on May 5 at 8:30 a.m. EDT to share 1Q 2026 results and key updates, including progress toward key catalysts in 2026. #QuarterlyUpdate #Biotech $OCGN
Details: bit.ly/4w6c9H5
Replay: ir.ocugen.com/
20
100
3,202
On April 28, CEO @drsmusunuri and Abhi Gupta, EVP of Commercial and BD will present at global biotech conferences, sharing updates on our #genetherapy platform and progress toward our first BLA submission and commercialization. 🔗bit.ly/4e5oKnd @Oppenheimer @alliancerm
16
81
3,145
Susan, an #OCU410ST participant, saw stabilization in her treated eye after #Stargardtdisease treatment, while the untreated eye declined. Now in Phase 2/3, OCU410ST could become the first approved therapy for Stargardt disease. Follow us for updates.
22
116
10,556